Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Cheng, Ann‐Lii; Qin, Shukui; Ikeda, Masafumi; R. Galle, Peter; Ducreux, Michel; Kim, Tae‐You; Yeong Lim, Ho; Kudo, Masatoshi; В. Бредер, В.; Merle, Philippe; O. Kaseb, Ahmed; Li, Daneng; Verret, Wendy; Ma, Ning; Nicholas, Alan; Wang, Yifan; Li, Lindong; X. Zhu, Andrew; S. Finn, Richard

doi:10.1016/j.jhep.2021.11.030

Public

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Published in Journal of Hepatology • Dec 11, 2021

Authors:

Ann‐Lii Cheng

Shukui Qin

Masafumi Ikeda

Abstract

BACKGROUND & AIMS: IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared with sorafenib in patients with unresectable hepatocellular carcinoma at the primary analysis (after a median 8.6 months of f...

Subject

Atezolizumab

Bevacizumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!